Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen Journal Article

   

Authors:	Chekmasova, A. A.; Rao, T. D. ; Nikhamin, Y.; Park, K. J.; Levine, D. A.; Spriggs, D. R.; Brentjens, R. J.
Article Title:	Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen
Abstract:	Purpose: Most patients diagnosed with ovarian cancer will ultimately die from their disease. For this reason, novel approaches to the treatment of this malignancy are needed. Adoptive transfer of a patient's own T cells, genetically modified ex vivo through the introduction of a gene encoding a chimeric antigen receptor (CAR) targeted to a tumor-associated antigen, is a novel approach to the treatment of ovarian cancer. Experimental Design: We have generated several CARs targeted to the retained extracellular domain of MUC16, termed MUC-CD, an antigen expressed on most ovarian carcinomas. We investigate the in vitro biology of human T cells retrovirally transduced to express these CARs by coculture assays on artificial antigen-presenting cells as well as by cytotoxicity and cytokine release assays using the human MUC-CD+ ovarian tumor cell lines and primary patient tumor cells. Further, we assess the in vivo antitumor efficacy of MUC-CD-targeted T cells in SCID-Beige mice bearing peritoneal human MUC-CD+ tumor cell lines. Results: CAR-modified, MUC-CD-targeted T cells exhibited efficient MUC-CD-specific cytolytic activity against both human ovarian cell and primary ovarian carcinoma cells in vitro. Furthermore, expanded MUC-CD-targeted T cells infused through either i.p. injection or i.v. infusion into SCID-Beige mice bearing orthotopic human MUC-CD+ ovarian carcinoma tumors either delayed progression or fully eradicated disease. Conclusion: These promising preclinical studies justify further investigation of MUC-CD-targeted T cells as a potential therapeutic approach for patients with high-risk MUC16+ ovarian carcinomas. ©2010 AACR.
Keywords:	unclassified drug; human cell; nonhuman; t lymphocyte; ovarian neoplasms; t-lymphocytes; animal cell; mouse; animals; mice; peritoneal neoplasms; animal experiment; animal model; membrane proteins; antineoplastic activity; cytotoxicity; in vitro study; mice, scid; tumor cells, cultured; xenograft model antitumor assays; tumor antigen; ovary tumor; tumor cell line; tumor cell; retrovirus vector; adoptive transfer; ca-125 antigen; cytokine release; antigen presenting cell; immunotherapy, adoptive; scid mouse; muc16 antigen; cytotoxicity tests, immunologic
Journal Title:	Clinical Cancer Research
Volume:	16
Issue:	14
ISSN:	1078-0432
Publisher:	American Association for Cancer Research
Date Published:	2010-07-15
Start Page:	3594
End Page:	3606
Language:	English
DOI:	10.1158/1078-0432.ccr-10-0192
PUBMED:	20628030
PROVIDER:	scopus
PMCID:	PMC2907178
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-77954712252&partnerID=40&md5=c4a2f0801e811ce1b15e017505820d7e
Notes:	--- - "Export Date: 20 April 2011" - "CODEN: CCREF" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/3855